HTCR

HeartCore Enterprises, Inc. (HTCR) - 10-K Summary

Business Context and Reporting Period

Company: HeartCore Enterprises, Inc.
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Headquarters: Tokyo, Japan (Delaware incorporation)
Business Model: A software development company operating through two primary divisions: Customer Experience Management (CXM) and Digital Transformation (DX). The company also operates a "GO IPO" consulting business assisting Japanese companies with U.S. listings.

Key Financial Metrics (Year Ended Dec 31, 2024)

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 39.2% year-over-year, driven primarily by a $8.5 million increase in consulting services revenue. This was largely due to two clients successfully listing on Nasdaq, triggering the recognition of $13.5 million in non-cash consideration (warrants and shares).
• Impairment Charges: The company recorded significant non-cash impairment charges in 2024 that were absent in 2023:
  • Impairment of Intangible Assets: $3,878,125
  • Impairment of Goodwill: $3,276,441
• Loss on Sale of Warrants: A loss of $3,970,628 was recorded in 2024 from the sale of warrants received from a consulting customer.
• Operating Expenses: Total operating expenses increased 45.8% to $17.8 million, primarily due to the impairment charges noted above. Excluding impairments, core operating expenses (Selling, G&A, R&D) decreased.
• Dividends: The company paid two cash dividends in 2024 totaling $834,566 ($0.02 per share each), whereas no dividends were paid in 2023.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• GO IPO Business: Management views the consulting business as a key offset to declines in traditional software sales. As of Dec 31, 2024, the company has agreements with 14 companies for IPO assistance.
• International Expansion: The company plans to continue investing in international sales and marketing, particularly in North America, which represented 25.83% of total revenues in 2024.
• Dividend Policy: The Board may continue to issue quarterly dividends contingent on financial results, though future amounts are not guaranteed.

• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2024, due to a material weakness regarding insufficient financial reporting personnel with appropriate U.S. GAAP knowledge.
• Concentration Risk: One customer accounted for 43.8% of total revenues in 2024.
• Equity Rights Volatility: A significant portion of revenue and assets is tied to warrants and equity rights from IPO clients, which are subject to market volatility and may become worthless if clients fail to list.
• Delisting Risk: The company notes risks regarding the Holding Foreign Companies Accountable Act (HFCA) if the PCAOB cannot inspect its auditor, though the auditor (MaloneBailey) is currently compliant.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 39% revenue growth, specifically the portion derived from non-cash warrant consideration ($13.5M) versus cash collections.
• Impairment Rationale: Review the third-party valuation reports supporting the full write-down of goodwill and intangible assets related to the Sigmaways acquisition.
• Internal Control Remediation: Assess the plan and timeline for remedying the material weakness in internal controls over financial reporting.
• Cash Flow vs. Net Income: Note that while Net Loss attributable to HeartCore improved significantly, Net Cash Used in Operating Activities increased to $4.8M due to non-cash adjustments and working capital changes.
• Customer Concentration: Evaluate the risk associated with the single customer representing 43.8% of 2024 revenue.